KDventures’ portfolio company Umecrine Cognition reports last patient out in Phase 1b/2a study evaluating golexanolone in primary biliary cholangitis
STOCKHOLM, Sweden, September 15, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company Umecrine Cognition has reported that the last patient has completed the final follow-up visit in the company’s Phase 1b/2a study of golexanolone in patients with primary biliary c…